Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vonoprazan Fumarate

FDA-approved product (tablet, oral), marketed as Voquezna.

Registered studies
24
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Vonoprazan Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Gastroesophageal reflux disease
  • Peptic ulcer

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Proton pump inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vonoprazan Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vonoprazan Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin

    NCT05135182 · start 2021-11-28

    Registered record
    Registry ID
    NCT05135182
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Furazolidone; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-11-28
    Completion
    2022-12
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionFurazolidone; Metronidazole
    PhasePhase 4
    Registry statusUnknown

  • Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin

    NCT05129176 · start 2021-11-23

    Registered record
    Registry ID
    NCT05129176
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Levofloxacin; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-11-23
    Completion
    2022-11
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionLevofloxacin; Metronidazole
    PhasePhase 4
    Registry statusUnknown

  • Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

    NCT05049902 · start 2021-09-21

    Registered record
    Registry ID
    NCT05049902
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-09-21
    Completion
    2023-06-30
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 more
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection

    NCT04991584 · start 2021-08-04

    Registered record
    Registry ID
    NCT04991584
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-04
    Completion
    2022-07-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
    PhaseNot applicable
    Registry statusUnknown

  • The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori

    NCT04850209 · start 2021-07-23

    Registered record
    Registry ID
    NCT04850209
    Conditions
    Helicobacter Pylori Infection; Helicobacter Pylori Eradication; Patient Education
    Interventions
    oral and written education; Wechat group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-07-23
    Completion
    2022-09-10
    Enrolment
    438

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection; Helicobacter Pylori Eradication; Patient Education
    Interventionoral and written education; Wechat group
    PhaseNot applicable
    Registry statusCompleted

  • Differences in the Eradication of Helicobacter Pylori by Different Therapies

    NCT05097846 · start 2021-06-17

    Registered record
    Registry ID
    NCT05097846
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Group1 Vonoprazan Fumarate + amoxicillin + doxycycline; Group2 Vonoprazan Fumarate + furazolidone + doxycycline; Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline; Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-06-17
    Completion
    2022-10-17
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionGroup1 Vonoprazan Fumarate + amoxicillin + doxycycline; Group2 Vonoprazan Fumarate + furazolidone + doxycycline; Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline; Group4 esomeprazole + colloidal bismuth tartrate + furazolidone + doxycycline
    PhaseNot applicable
    Registry statusUnknown

  • Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

    NCT04901117 · start 2021-06

    Registered record
    Registry ID
    NCT04901117
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Amoxicillin; Clarithromycin; Tetracycline; Metronidazole; Bismuth Potassium Citrate; Colloidal Bismuth Pectin; Vonoprazan fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06
    Completion
    2023-08
    Enrolment
    1,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionAmoxicillin; Clarithromycin; Tetracycline; Metronidazole +3 more
    PhasePhase 4
    Registry statusUnknown

  • The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

    NCT04810793 · start 2020-07-01

    Registered record
    Registry ID
    NCT04810793
    Conditions
    Helicobacter Pylori
    Interventions
    Amoxicillin , Levofloxacin and Esomeprazole; Amoxicillin , Furazolidone and Esomeprazole; Tetracycline , Furazolidone and Esomeprazole; Amoxicillin,Levofloxacin and Vonoprazan fumarate; Amoxicillin,Furazolidone and Vonoprazan fumarate; Tetracycline,Furazolidone and Vonoprazan fumarate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2022-06-30
    Enrolment
    820

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori
    InterventionAmoxicillin , Levofloxacin and Esomeprazole; Amoxicillin , Furazolidone and Esomeprazole; Tetracycline , Furazolidone and Esomeprazole; Amoxicillin,Levofloxacin and Vonoprazan fumarate +2 more
    PhaseNot recorded
    Registry statusCompleted

  • Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

    NCT02679508 · start 2016-03-20

    Registered record
    Registry ID
    NCT02679508
    Conditions
    Erosive Esophagitis
    Interventions
    Vonoprazan; Lansoprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-03-20
    Completion
    2022-03-05
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErosive Esophagitis
    InterventionVonoprazan; Lansoprazole
    PhasePhase 4
    Registry statusCompleted